MX366654B - Formulación farmacéutica. - Google Patents

Formulación farmacéutica.

Info

Publication number
MX366654B
MX366654B MX2015009455A MX2015009455A MX366654B MX 366654 B MX366654 B MX 366654B MX 2015009455 A MX2015009455 A MX 2015009455A MX 2015009455 A MX2015009455 A MX 2015009455A MX 366654 B MX366654 B MX 366654B
Authority
MX
Mexico
Prior art keywords
corticosteroid
insoluble
soluble
injection
intra
Prior art date
Application number
MX2015009455A
Other languages
English (en)
Other versions
MX2015009455A (es
Inventor
Mahendra G Shah
Original Assignee
Semnur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semnur Pharmaceuticals Inc filed Critical Semnur Pharmaceuticals Inc
Publication of MX2015009455A publication Critical patent/MX2015009455A/es
Publication of MX366654B publication Critical patent/MX366654B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas acuosas que proporcionan administración de liberación sostenida de compuestos de corticosteroides. La composición farmacéutica comprende un corticosteroide insoluble; un corticosteroide soluble; y al menos un agente mejorador de viscosidad. También se proporcionan métodos para usar las composiciones farmacéuticas en una inyección epidural, inyección intraarticular, inyección intra-lesional, o una inyección intra-ocular.
MX2015009455A 2013-01-23 2014-01-23 Formulación farmacéutica. MX366654B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361755723P 2013-01-23 2013-01-23
US201361776617P 2013-03-11 2013-03-11
PCT/US2014/012824 WO2014116876A1 (en) 2013-01-23 2014-01-23 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid

Publications (2)

Publication Number Publication Date
MX2015009455A MX2015009455A (es) 2016-01-12
MX366654B true MX366654B (es) 2019-07-17

Family

ID=50097866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009455A MX366654B (es) 2013-01-23 2014-01-23 Formulación farmacéutica.

Country Status (14)

Country Link
US (4) US9833460B2 (es)
EP (1) EP2948182B1 (es)
JP (1) JP6215354B2 (es)
KR (1) KR102055937B1 (es)
CN (1) CN105073138B (es)
AU (2) AU2014209346B2 (es)
BR (1) BR112015017246B1 (es)
CA (1) CA2897467C (es)
HK (1) HK1218074A1 (es)
IL (1) IL239791B (es)
MX (1) MX366654B (es)
NZ (1) NZ709620A (es)
TW (1) TWI624262B (es)
WO (1) WO2014116876A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
BR112015017246B1 (pt) * 2013-01-23 2022-11-29 Semnur Pharmaceuticals, Inc Composição farmacêutica aquosa injetável, seu uso e seringa
TWI845973B (zh) * 2015-01-21 2024-06-21 美商桑紐爾製藥公司 醫藥配方
JP2018516910A (ja) 2015-06-02 2018-06-28 ニューサウス・イノベーションズ・ピーティーワイ・リミテッド 神経外傷を制限するための処方物および方法
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
WO2020118045A1 (en) * 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Injectable formulations
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
US11382863B2 (en) * 2020-03-04 2022-07-12 Somerset Therapeutics Llc Injectable suspension comprising an insoluble corticosteroid and a soluble corticosteroid
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用
CN116367840A (zh) * 2020-10-22 2023-06-30 辉瑞公司 用于皮质类固醇胃肠外给药的无peg的水性混悬液

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25251A (en) 1965-07-20 1969-11-12 Merck & Co Inc Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
FI105075B (fi) 1996-01-10 2000-06-15 Suprakort Oy Kombinaatioinjektiovalmisteen käyttö
IT1288290B1 (it) 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
JPH11279065A (ja) 1998-03-25 1999-10-12 Shiseido Co Ltd 局所投与炎症治療剤
US6921532B1 (en) * 2000-06-22 2005-07-26 Spinal Restoration, Inc. Biological Bioadhesive composition and methods of preparation and use
US6747090B2 (en) * 2001-07-16 2004-06-08 Pharmacia Groningen Bv Compositions capable of forming hydrogels in the eye
US20040006052A1 (en) 2002-04-15 2004-01-08 Gudas Charles J. Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050186229A1 (en) 2004-02-24 2005-08-25 Emmett Clemente Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate
JP2007001926A (ja) * 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
JP4969812B2 (ja) 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
US20070099882A1 (en) 2005-10-27 2007-05-03 Gurney Harry C Methods and compositions for prolonged alleviation of articular joint pain
WO2007070547A2 (en) * 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
CN100534434C (zh) * 2006-05-15 2009-09-02 西安力邦制药有限公司 透明质酸钠地塞米松脂肪乳制剂及其应用
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9421356B2 (en) * 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090143807A1 (en) 2007-12-03 2009-06-04 Vertos Medical, Inc., A Delaware Corporation Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same
JP2011513337A (ja) * 2008-04-18 2011-04-28 ウォーソー・オーソペディック・インコーポレーテッド 椎間板ヘルニアを治療するための方法および組成物
CN102026623B (zh) * 2008-05-14 2013-08-14 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
WO2010054356A1 (en) * 2008-11-10 2010-05-14 Nitric Biotherapeutics, Inc. Pharmaceutical formulations for iontophoretic delivery of a corticosteroid
JP5683587B2 (ja) * 2009-07-30 2015-03-11 カービラン バイオサージェリー， インコーポレイテッド 修飾ヒアルロン酸ポリマー組成物および関連する方法
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2459615C1 (ru) 2011-03-05 2012-08-27 Илья Александрович Марков Глазные капли для лечения болезни сухого глаза
WO2013085769A1 (en) 2011-12-06 2013-06-13 Alcon Research, Ltd. Cellulosic gel composition with improved viscosity stability
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
BR112015017246B1 (pt) * 2013-01-23 2022-11-29 Semnur Pharmaceuticals, Inc Composição farmacêutica aquosa injetável, seu uso e seringa
TWI845973B (zh) 2015-01-21 2024-06-21 美商桑紐爾製藥公司 醫藥配方

Also Published As

Publication number Publication date
AU2019200649A1 (en) 2019-02-21
US20220370476A1 (en) 2022-11-24
NZ709620A (en) 2020-07-31
US20140356434A1 (en) 2014-12-04
MX2015009455A (es) 2016-01-12
IL239791B (en) 2020-11-30
US12016867B2 (en) 2024-06-25
CN105073138A (zh) 2015-11-18
US9833460B2 (en) 2017-12-05
IL239791A0 (en) 2015-08-31
US10744144B2 (en) 2020-08-18
CA2897467A1 (en) 2014-07-31
WO2014116876A8 (en) 2015-08-20
BR112015017246A8 (pt) 2019-10-29
AU2019200649B2 (en) 2020-02-27
CN105073138B (zh) 2018-06-05
KR102055937B1 (ko) 2019-12-13
AU2014209346A1 (en) 2015-07-23
US11364251B2 (en) 2022-06-21
JP2016510329A (ja) 2016-04-07
BR112015017246B1 (pt) 2022-11-29
TWI624262B (zh) 2018-05-21
AU2014209346B2 (en) 2018-11-15
WO2014116876A1 (en) 2014-07-31
KR20150114505A (ko) 2015-10-12
CA2897467C (en) 2020-09-22
US20210052605A1 (en) 2021-02-25
BR112015017246A2 (pt) 2017-07-11
JP6215354B2 (ja) 2017-10-18
EP2948182B1 (en) 2020-09-30
EP2948182A1 (en) 2015-12-02
US20180235980A1 (en) 2018-08-23
TW201442713A (zh) 2014-11-16
HK1218074A1 (zh) 2017-02-03

Similar Documents

Publication Publication Date Title
NZ709620A (en) Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
MX2021012029A (es) Composicion farmaceutica de corticosteroide soluble.
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
NZ712350A (en) Abiraterone acetate formulation
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
EP3072506A4 (en) Carrier for drug delivery and conjugate, composition containing same, and method for administering same
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
MX347014B (es) Composición para administración de fármaco biodegradable.
PH12015501096A1 (en) Composition for immediate and extended release
WO2014153009A3 (en) Thiosaccharide mucolytic agents
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
PH12015501982A1 (en) Pharmaceutical compositions comprising everolimus
PH12014502571A1 (en) Ophthalmic compositions with improved dessication protection and retention
EP3679608A4 (en) TRIPLET-TRIPLET ANNIHILATION CONVERSION-ELEVATION SYSTEM, AND ASSOCIATED COMPOSITIONS AND METHODS FOR DRUG DELIVERY
MX2019015527A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
MX2022012075A (es) Formulaciones de farmacos de moleculas peque?as resistentes a precipitacion.
WO2014107596A8 (en) Compositions and methods for polynucleotide transfection
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
MX2020007270A (es) Formulacion parenteral que comprende siponimod.
MX2018009739A (es) La administración combinada de un agente de penetración y un compuesto que contiene azufre a plantas.
SG10201810362SA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition
EP4360628A3 (en) Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

Legal Events

Date Code Title Description
FG Grant or registration